An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00297414|
Recruitment Status : Completed
First Posted : February 28, 2006
Last Update Posted : April 12, 2012
|Condition or disease||Intervention/treatment|
|Mild Cognitive Impairment||Other: No intervention|
|Study Type :||Observational|
|Actual Enrollment :||1083 participants|
|Official Title:||An Analysis of Mortality in Subjects Who Participated in Three Studies of Galantamine in Mild Cognitive Impairment|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||January 2005|
|Actual Study Completion Date :||January 2005|
Patients with mild cognitive impairment
Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
Other: No intervention
No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
- To evaluate vital status of patients enrolled in 3 galantamine studies [ Time Frame: 4 weeks ]Poststudy vital status (living or deceased) of patients who participated in 3 clinical studies with galantamine will be evaluated. Data will be collected as vital status of the patient, date of death, cause of death and adverse events associated with death.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00297414
Show 145 Study Locations
|Study Director:||Johnson & Johnson Pharmaceutical Research & Development, LLC C. Clinical Trial||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|